Skip to main content

Table 3 Safety of Bevacizumab plus Paclitaxel (total patients n= 35)

From: Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

Toxicity Grade 1 Grade 2 Grade 3 Grade 4
n(%) n(%) n(%) n(%)
Bleeding 1 (2.8) - 1 (2.8) -
Protenuria - - - -
Hypertension - 2 (5.7)   -
Neurotoxicity 1 (2.8) 2 (5.7) - -
LVS disfunction 1 (2.8) - - -